

DCVMN AGM – Inaugural Session



Sai D Prasad
20 Oct 2022

DCVMN
Developing Countries Vaccine
Manufactures Network



- DCVMN Overview
- DCVMN Pandemic Response & Industry Feedback
- Ecosystem for Vaccine Industry
- DCVMN Future Direction
- DCVMN Board Activities

Contents



DCVMN OVERVIEW

- 40+ Innovators and vaccine manufacturers, across 15 countries
- Representing all WHO regions
- More than 50 distinct vaccines, supplied to ~ 170 countries

- ~15 WHO Prequalified vaccine manufacturers
- ~78 prequalified vaccines




DCVM's PANDEMIC RESPONSE

- 9 manufactures developed innovative vaccines
 - Inactivated vaccines, Ad-vectored vaccines, DNA vaccines, Sub-unit vaccines, mRNA vaccines, etc
 - Success in Product development
- ~ Over 11 manufacturers are recipients of technology transfers
 - Ad-vectored vaccines, Inactivated vaccines, Sub-unit vaccines, mRNA vaccines etc
- DCVM's : >50% of global supplies
 - > 8 billion doses
 - Success in Large Scale Manufacturing
- Excellent achievement in technology and Manufacturing,
 - Failure towards equitable access
 - Failure in Financing and Procurement



HEADWINDS FOR INDUSTRY

Pandemic Funding



■ Others ■ DCVMN members

R & D Funding:
\$ 5.6* Billion in 2020-21

- > 50% of COVID-19 vaccines supplied by DCVM's,

Need for reflection : disproportionate allocation vs success rate of deployed funding



COVID19 Vaccines

Global Equitable Access

Industry Feedback

- Pandemic Convention / Pandemic Treaty
 - The convention to provide guidance for the free flow of goods, services, knowledge, between countries, During pandemics,
 - To avoid political, financial, trade, knowledge based barriers etc
- Procurement agencies were more favourable to provide purchase commitments to companies in North America, EU etc,
 - DCVM's mostly ignored
 - But > 50% manufacturing and supplies from DCVM's



COVID19 Vaccines

Global Equitable Access

Industry Feedback

- Product development Funding agencies were quick to provide funding support to novel and innovative but unproven technologies,
 - Poor understanding of
 - large scale manufacturing capabilities,
 - programmatic suitability,
 - supply and distribution track record,
 - etc,
 - DCVM's with traditional technologies, and large manufacturing / distribution capabilities were ignored



Ecosystem for Vaccine Industry

- Lack of sustainable pricing for an healthy industry
 - Constant downward pressure on vaccines pricing with the intent of making it affordable,
 - Reduction in # of suppliers, market exits by suppliers,
 - Consolidation of existing supplier base with vaccines,
 - Progression towards large volume manufacturers at low cost,
- Access to technology
 - Complex and varied,
 - but accessible,
- Long lead times for vaccinology
 - Vaccine development, regulatory approvals – 10 -15 years,
 - Facility development, qualifications, validations, regulatory approvals, - 5-7 years,
 - Investment size ~ > \$ 100 million ???
 - Regulatory approvals ~ 2-3 years in each country, post approval in first country,
 - Market access and distribution scale up ~ 5 years post regulatory approvals,
 - ROI ~ 10 years post regulatory approvals,



Ecosystem for Vaccine Industry

1. Human capital
 - Biological sciences, Chemistry, Mathematics, Statistics, pharmaceuticals, etc
 - Engineering, chemical, mechanical, electrical, electronics, computer sciences, etc
 - Medicine, veterinary sciences, epidemiology, etc
2. Academic research environment
3. Vendors and suppliers : network / ecosystem
4. Financing : readily available
 - Long term low cost debt,
 - private equity,
5. Global Logistics and distribution access
6. **Stable political environment**
7. **Strong regulatory system**
8. **Sustainable pricing for an healthy industry**



- Vaccines / Vaccinations – Advocacy
- Learning Agenda
 - Webinars, Workshops, Vaccinology courses,
- Regulatory Systems Harmonization
 - CRP, testing, audits, clinical trials, etc
- Healthy and Sustainable Industry
 - Value based pricing
 - Innovation driven product development
 - Partnerships

DCVMN Activities



Input : Working Groups

- Supply Chain
- Regulatory Affairs
- Pharmacovigilance
- 3Rs / PSPT
- COVID Committee
- Clinical & Medical affairs

Output : Internal / External Communications

- Position Papers
- Publications
- Stakeholder Communication

DCVMN Activities



DCVMN

**Annual General Meeting
2022**

Thank You

- 433 Attendees
- 41 Member companies
- 29 Attending in Person

- 37 Countries

- 38 Guest Organizations /
Companies / Sponsors